391 related articles for article (PubMed ID: 12944058)
1. Acetylcysteine for prevention of contrast nephropathy: meta-analysis.
Birck R; Krzossok S; Markowetz F; Schnülle P; van der Woude FJ; Braun C
Lancet; 2003 Aug; 362(9384):598-603. PubMed ID: 12944058
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis.
Duong MH; MacKenzie TA; Malenka DJ
Catheter Cardiovasc Interv; 2005 Apr; 64(4):471-9. PubMed ID: 15789388
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the prevention of radiocontrast-induced nephropathy.
Marenzi G; Bartorelli AL
Curr Opin Crit Care; 2004 Dec; 10(6):505-9. PubMed ID: 15616393
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.
Kelly AM; Dwamena B; Cronin P; Bernstein SJ; Carlos RC
Ann Intern Med; 2008 Feb; 148(4):284-94. PubMed ID: 18283206
[TBL] [Abstract][Full Text] [Related]
5. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury.
Drager LF; Andrade L; Barros de Toledo JF; Laurindo FR; Machado César LA; Seguro AC
Nephrol Dial Transplant; 2004 Jul; 19(7):1803-7. PubMed ID: 15128882
[TBL] [Abstract][Full Text] [Related]
6. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
Boccalandro F; Amhad M; Smalling RW; Sdringola S
Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
[TBL] [Abstract][Full Text] [Related]
7. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.
Misra D; Leibowitz K; Gowda RM; Shapiro M; Khan IA
Clin Cardiol; 2004 Nov; 27(11):607-10. PubMed ID: 15562929
[TBL] [Abstract][Full Text] [Related]
8. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
[TBL] [Abstract][Full Text] [Related]
9. Acetylcysteine for the prevention of radiocontrast -induced nephropathy.
Tepel M
Minerva Cardioangiol; 2003 Oct; 51(5):525-30. PubMed ID: 14551521
[TBL] [Abstract][Full Text] [Related]
10. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.
Nallamothu BK; Shojania KG; Saint S; Hofer TP; Humes HD; Moscucci M; Bates ER
Am J Med; 2004 Dec; 117(12):938-47. PubMed ID: 15629733
[TBL] [Abstract][Full Text] [Related]
11. [New usage for an old drug: acetylcysteine for contrast-induced nephropathy].
Asher I; Hammerman A; Sthoeger Z
Harefuah; 2005 Sep; 144(9):642-6; 675. PubMed ID: 16218537
[TBL] [Abstract][Full Text] [Related]
12. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT).
ACT Investigators
Circulation; 2011 Sep; 124(11):1250-9. PubMed ID: 21859972
[TBL] [Abstract][Full Text] [Related]
13. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials.
Dai B; Liu Y; Fu L; Li Y; Zhang J; Mei C
Am J Kidney Dis; 2012 Sep; 60(3):360-70. PubMed ID: 22516682
[TBL] [Abstract][Full Text] [Related]
14. Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.
Brophy DF
Ann Pharmacother; 2002 Sep; 36(9):1466-70. PubMed ID: 12196069
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
[TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis of contrast-induced nephropathy with N-acetylcysteine].
Gawenda M; Möller A; Wassmer G; Brunkwall J
Zentralbl Chir; 2007 Jun; 132(3):227-31. PubMed ID: 17610195
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
[TBL] [Abstract][Full Text] [Related]
18. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials.
Alonso A; Lau J; Jaber BL; Weintraub A; Sarnak MJ
Am J Kidney Dis; 2004 Jan; 43(1):1-9. PubMed ID: 14712421
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis.
Zhang B; Liang L; Chen W; Liang C; Zhang S
BMJ Open; 2015 Mar; 5(3):e006989. PubMed ID: 25783425
[TBL] [Abstract][Full Text] [Related]
20. [Use of N-acetylcysteine prior to cardiac catheterization to prevent acute renal injury in patients with stage III chronic kidney disease].
Shavit L; Lifschitz M; Lachish T; Rosenmann D; Balkin J; Slotki I
Harefuah; 2007 Sep; 146(9):655-9, 736. PubMed ID: 17969299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
